Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 – Submission of Matters to a Vote of Security Holders

The 2018 Annual Meeting of Shareholders (the “Annual Meeting”) of Synergy Pharmaceuticals Inc. (the “Company”) was held on June12, 2018. At the Annual Meeting, the shareholders voted on the following six (6)proposals and cast their votes as described below.

Proposal 1 — Election of Directors

The following seven (7)individuals were elected as directors, to serve until the 2019 Annual Meeting of Shareholders or their successors are elected and qualified with the following votes:

Proposal 2 — Advisory Vote on the Approval of Executive Compensation

The shareholders did not support our Named Executive Officer compensation as disclosed in this Proxy Statement and the accompanying Annual Report on Form10-K for the fiscal year ended December31, 2017 based on the votes below:

Proposal 3 — Advisory Vote on the Frequency of Holding an Advisory Vote on Executive Compensation

The shareholders approved "One Year" for the frequency of advisory votes on executive compensation based on the votes listed below:

Proposal 4 — Ratification of the appointment of BDO USA, LLP

The shareholders ratified and approved the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December31, 2018 based on the votes listed below:

Proposal 5 — Approval of Amendment to Second Amended and Restated Certificate of Incorporation

The shareholders did not approve the amendment to the Company’s Second Amended and Restated Certificate of Incorporation, as amended, increasing the number of shares of common stock authorized for issuance from 400,000,000 to 500,000,000 based on the votes listed below:

Proposal 6 — Approval of an Amendment to the 2017 Equity Incentive Plan

The shareholders did not approve the amendment to Synergy Pharmaceuticals Inc. 2017 Equity Incentive Plan to increase the maximum number of shares authorized for issuance under the Plan by 10,400,000 shares from 9,000,000 shares to 19,400,000 shares based on the votes listed below:

Each of the items considered at the Annual Meeting is described in further detail in the Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April20, 2018. No item other than the six items addressed above and described in the Definitive Proxy Statement was submitted at the Annual Meeting for shareholder action.

About Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)

Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease. Plecanatide is the Company’s uroguanylin analog being evaluated for use as a once-daily tablet for two functional GI disorders, chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Plecanatide is a 16-amino acid peptide that is structurally identical to uroguanylin with the exception of a single amino acid change. Dolcanatide is also its uroguanylin analog being explored for inflammatory bowel disease (IBD). Dolcanatide is designed to be an analog of uroguanylin with resistance to standard digestive breakdown by proteases in the intestine.